

PRODUCT DATASHEET

ChemiScreen™ FP Prostanoid Receptor Stable Cell Line

CATALOG NUMBER: HTS093C

CONTENTS: 2 vials of mycoplasma-free cells, 1 mL per vial.

STORAGE: Vials are to be stored in liquid N₂.

BACKGROUND

ChemiScreen cell lines are constructed in the Chem-1 host, which supports high levels of functional receptor expression on the cell surface. Chem-1 cells contain high endogenous levels of Gα15, a promiscuous G protein, allowing most receptors to couple to the calcium signaling pathway.

Prostanoids are a series of arachidonic acid metabolites produced by the action of cyclooxygenase and subsequently by isomerases and synthases. Cells rapidly secrete prostanoids after synthesis, whereupon the prostanoids bind to a family of 8 GPCRs to exert their biological effects (Narumiya and FitzGerald, 2001). The prostaglandin PGF_{2a} binds specifically to the FP receptor, which couples to G_{q/11} to mobilize intracellular calcium. Binding of PGF_{2a} to FP receptors in the corpus luteum is required for luteolysis and subsequent parturition in mice (Sugimoto *et al.*, 1998). PGF_{2a} also decreases intraocular pressure by an FP-dependent mechanism, and an PGF_{2a} analog, latanoprost, is used clinically in the treatment of glaucoma (Crowston *et al.*, 2004). FP also contributes to tachycardia induced by inflammatory stimuli (Takayama *et al.*, 2005). The cloned human FP-expressing cell line is made in the Chem-1 host, which supports high levels of recombinant FP expression on the cell surface and contains high levels of the promiscuous G protein Gα15 to enhance coupling of the receptor to the calcium signaling pathway. Thus, the cell line is an ideal tool for screening for antagonists of interactions between FP and its ligands.

USE RESTRICTIONS

Please see User Agreement (Label License) for further details.

WARNINGS

For Research Use Only; Not for Use in Diagnostic Procedures
Not for Animal or Human Consumption

GMO

This product contains genetically modified organisms.
Este producto contiene organismos genéticamente modificados.
Questo prodotto contiene degli organismi geneticamente modificati.
Dieses Produkt enthält genetisch modifizierte Organismen.
Ce produit contient organismes génétiquement des modifiés.
Dit product bevat genetisch gewijzigde organismen.
Tämä tuote sisältää geneettisesti muutettuja organismeja.
Denna produkt innehåller genetiskt ändrade organismer.

APPLICATIONS

Calcium Flux Fluorescence Assay

APPLICATION DATA




Figure 1. Representative data for activation of the FP receptor stably expressed in Chem-1 cells induced by PGF_{2α} using a fluorescent calcium flux assay. FP-expressing Chem-1 cells were seeded at 50,000 cells per well into a 96-well plate, and the following day the cells were loaded with a fluorescent calcium indicator. Calcium flux in response to the indicated ligand with a final concentration of 0.5% DMSO was determined on a Molecular Devices FLIPR^{TETRA}® with ICCD camera. Maximal fluorescence signal obtained in this experiment was 9,000 RLU. Similarly parental cells (catalog #: HTSCHEM-1) were tested to determine the specificity of the resulting signal.

Table 1. EC₅₀ value of FP-expressing Chem-1 cells.

LIGAND	ASSAY	POTENCY EC ₅₀ (nM)	REFERENCE
PGF _{2α}	Calcium Flux - Fluorescence	45	Eurofins Internal Data

* The cell line was tested and found to have equivalent EC₅₀ and signal at 1, 3 and 6 weeks of continuous culture by calcium flux fluorescence.

CELL CULTURE

Table 2. Recommended Cell Culture Reagents (not provided)

Description	Component	Concentration	Supplier and Product Number
Basal Medium	DMEM high glucose Medium (4.5g/L)	-	Hyclone: SH30022
	Fetal Bovine Serum (FBS)	10%	Hyclone: SH30070.03
	Non-Essential Amino Acids (NEAA)	1X	Hyclone: SH30238.01
	HEPES	1X	EMD Millipore: TMS-003-C
	Selection Medium	Basal Medium (see above)	-
Dissociation	Geneticin (G418)	250 µg/ml	Invivogen: ant-gn-5
	Sterile PBS	-	Hyclone: SH30028.03
	0.25% Trypsin-EDTA	-	Hyclone: SH30042.01
CryoMedium	Basal Medium (see above)	40%	
	Fetal Bovine Serum (FBS)	50%	Hyclone: SH30070.03
	Dimethyl Sulfoxide (DMSO)	10%	Sigma: D2650

Cell Handling

1. Upon receipt, directly place cells in liquid nitrogen storage. Consistent cryopreservation is essential for culture integrity.
2. Prepare Basal Medium. Prepare 37°C Water Bath. Thaw cells rapidly by removing from liquid nitrogen, and immediately immersing in a 37°C water bath, until 90% thawed. Immediately sterilize the exterior of the vial with 70% ethanol.
3. Add vial contents to 15 mL Basal Medium in T75 Tissue Culture Treated Flask. Gently swirl flask and place in a humidified, tissue culture incubator, 37°C, 5% CO₂.
4. 18-24 Hours Post–Thaw, all live cells should be attached. Viability of the cells is expected to be 60-90%. At this time, exchange Basal Medium with Selection Medium.
5. When cells are approximately 80% confluent, passage the cells. It is suggested that user expand culture to create >20 vial Master Cell Bank at low passage number. *Cells should be maintained at less than 80% confluency for optimal assay results.*
6. Cell Dissociation: Aspirate Culture Medium. Gently wash with 1x Volume PBS. Add 0.1x Volume Warm Trypsin-EDTA. Incubate 4 min, 37°C, until cells dislodge. *If cells do not round up, place in 37° C incubator for additional 2 min.* Neutralize Trypsin and collect cells in 1x Volume Basal Medium.
7. Seed Cells for expansion of culture. It is recommended that cell lines are passaged at least once before use in assays.

Table 3. Cell Culture Seeding Suggestions: *User should define based on research needs.*

Flask Size (cm ²)	Volume (mL)	Total Cell Number (x10 ⁶)	Growth Period (hrs)
T75	15	5.0	24
T75	15	2.0	48
T75	15	0.45	72

ASSAY SETUP

Fluorescence

Table 4. Settings for FLIPR^{TETRA}® with ICCD camera option

Option	Setting
Read Mode	Fluorescence
Ex/Em	Ex470_495 / Em515_575
Camera Gain	2000
Gate Open	6 %
Exposure Time	0.53
Read Interval	1s
Dispense Volume	50 µl (25 µl for 384-well)
Dispense Height	95 µl (50 µl for 384-well)
Dispense Speed	50 µl/sec
Expel Volume	0 µl
Analysis	Subtract Bias Sample 1

Table 5. Assay Materials (Not provided)

Description	Supplier and Product Number
HBSS	Invitrogen: 14025
HEPES 1M Stock	EMD Millipore: TMS-003-C
Probenicid	Sigma: P8761
Quest Fluo-8™, AM	AAT Bioquest: 21080
PGF _{2α} ligand	Cayman: 16010
Non-Binding 96/384 well Plates (for ligand prep)	Corning: 3605/ 3574
Black (clear Bottom) cell assay plates	Corning: 3904/ 3712
Coelenterazine-h (250µg). Prepare to 10mM	Promega: S2011

Assay Protocol – Fluorescence

1. Dissociate Culture as Recommended. Collect in Basal Medium. Document Cell Count and Viability
2. Centrifuge the cell suspension at 190 x g for six min
3. Remove supernatant. Gently resuspend the cell pellet in Basal Medium. *It is suggested that end user optimize cell plating based on individual formats.* (Default: Resuspend in volume to achieve 5×10^5 cells/ml (i.e, if collected 5×10^6 TC, $\frac{5 \times 10^6}{5 \times 10^5/ml} = 10$ mL volume)
4. Seed cell suspension into black, clear bottom plate (100 µL/well for 96-well plate). *When seeding is complete, place the assay plate at room temperature for 30 min.*
5. Move assay plate to a humidified 37°C 5% CO₂ incubator for 18-24 h.
6. Next day, prepare Assay buffer (HBSS, 20mM HEPES, 2.5 mM Probenicid, pH 7.4) and Loading buffer (Assay buffer with 5 mM Fluo8 Dye). *Note: Please prepare Fluo8 stock according to Manufacturer's Recommendations*
7. Remove medium from assay plate and wash 1X with Assay Buffer.
8. Add Loading buffer to assay plate (100 µL/well for 96-well plate). Incubate plate for 1.5 h at room temperature, protected from light.
9. Prepare ligands in assay buffer at 3x final concentration in non-binding plates. Use Buffer Only Control Wells for Background Subtraction.
10. Create protocol for ligand addition. Please refer to FLIPR™^{TETRA}® settings provided in Table 2. Set time course for 180 s, with ligand addition at 10 s.
11. After the run is complete, apply subtract bias on sample 1. We recommend using Negative Control Correction with Buffer Only Wells. Export data to according to research needs. For most Calcium Flux analysis using Export of Max Signal to end of run is sufficient.

HOST CELL

Chem-1, an adherent cell line expressing the promiscuous G-protein, Gα15.

EXOGENOUS GENE EXPRESSION

Human FP cDNA (Accession Number: NM_000959; see CODING SEQUENCE below) and promiscuous G protein are expressed in a bicistronic vector

CODING SEQUENCE

```

                                     ATG TCC ATG AAC AAT TCC AAA CAG CTA GTG TCT CCT
                                     M  S  M  N  N  S  K  Q  L  V  S  P
GCA GCT GCG CTT CTT TCA AAC ACA ACC TGC CAG ACG GAA AAC CGG CTT TCC GTA TTT TTT TCA GTA ATC
A  A  A  L  L  S  N  T  T  C  Q  T  E  N  R  L  S  V  F  F  S  V  I
TTC ATG ACA GTG GGA ATC TTG TCA AAC AGC CTT GCC ATC GCC ATT CTC ATG AAG GCA TAT CAG AGA TTT
F  M  T  V  G  I  L  S  N  S  L  A  I  A  I  L  M  K  A  Y  Q  R  F
AGA CAG AAG TCC AAG GCA TCG TTT CTG CTT TTG ACC AGT GGC CTG GTA ATC ACT GAT TTC TTT GGC CAT
R  Q  K  S  K  A  S  F  L  L  L  A  S  G  L  V  I  T  D  F  F  G  H
CTC ATC AAT GGA GCC ATA GCA GTA TTT GTA TAT GCT TCT GAT AAA GAA TGG ATC CGC TTT GAC CAA TCA
L  I  N  G  A  I  A  V  F  V  Y  A  S  D  K  E  W  I  R  F  D  Q  S
AAT GTC CTT TGC AGT ATT TTT GGT ATC TGC ATG GTG TTT TCT GGT CTG TGC CCA CTT CTT CTA GGC AGT
N  V  L  C  S  I  F  G  I  C  M  V  F  S  G  L  C  P  L  L  L  G  S
GTG ATG GCC ATT GAG CGG TGT ATT GGA GTC ACA AAA CCA ATA TTT CAT TCT ACG AAA ATT ACA TCC AAA
V  M  A  I  E  R  C  I  G  V  T  K  P  I  F  H  S  T  K  I  T  S  K
CAT GTG AAA ATG ATG TTA AGT GGT GTG TGC TTG TTT GCT GTT TTC ATA GCT TTG CTG CCC ATC CTT GGA
H  V  K  M  M  L  S  G  V  C  L  F  A  V  F  I  A  L  L  P  I  L  G
CAT CGA GAC TAT AAA ATT CAG GCG TCG AGG ACC TGG TGT TTC TAC AAC ACA GAA GAC ATC AAA GAC TGG
H  R  D  Y  K  I  Q  A  S  R  T  W  C  F  Y  N  T  E  D  I  K  D  W
GAA GAT AGA TTT TAT CTT CTA CTT TTT TCT TTT CTG GGG CTC TTA GCC CTT GGT GTT TCA TTG TTG TGC
E  D  R  F  Y  L  L  L  F  S  F  L  G  L  L  A  L  G  V  S  L  L  C
AAT GCA ATC ACA GGA ATT ACA CTT TTA AGA GTT AAA TTT AAA AGT CAG CAG CAC AGA CAA GGC AGA TCT
N  A  I  T  G  I  T  L  L  R  V  K  F  K  S  Q  Q  H  R  Q  G  R  S
CAT CAT TTG GAA ATG GTA ATC CAG CTC CTG GCG ATA ATG TGT GTC TCC TGT ATT TGT TGG AGC CCA TTT
H  H  L  E  M  V  I  Q  L  L  A  I  M  C  V  S  C  I  C  W  S  P  F
CTG GTT ACA ATG GCC AAC ATT GGA ATA AAT GGA AAT CAT TCT CTG GAA ACC TGT GAA ACA ACA CTT TTT
L  V  T  M  A  N  I  G  I  N  G  N  H  S  L  E  T  C  E  T  T  L  F
GCT CTC CGA ATG GCA ACA TGG AAT CAA ATC TTA GAT CCT TGG GTA TAT ATT CTT CTA CGA AAG GCT GTC
A  L  R  M  A  T  W  N  Q  I  L  D  P  W  V  Y  I  L  L  R  K  A  V
CTT AAG AAT CTC TAT AAG CTT GCC AGT CAA TGC TGT GGA GTG CAT GTC ATC AGC TTA CAT ATT TGG GAG
L  K  N  L  Y  K  L  A  S  Q  C  C  G  V  H  V  I  S  L  H  I  W  E
CTT AGT TCC ATT AAA AAT TCC TTA AAG GTT GCT GCT ATT TCT GAG TCA CCA GTT GCA GAG AAA TCA GCA
L  S  S  I  K  N  S  L  K  V  A  A  I  S  E  S  P  V  A  E  K  S  A
AGC ACC TAG TGA
S  T      Stp

```

RELATED PRODUCTS

Product Number	Description
HTSCHEM-1	ChemiScreen™ Chem-1 Parental Cell Line (control cells)
HTS093M	ChemiScreen™ FP Prostanoid Receptor Membrane Prep

REFERENCES

1. Crowston JG *et al.* (2004) Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. *Invest. Ophthalmol. Vis. Sci.* 45: 3555-9.
2. Narumiya S and FitzGerald GA (2001) Genetic and pharmacological analysis of prostanoid receptor function. *J. Clin. Invest.* 108: 25-30.
3. Sugimoto Y *et al.* (1997) Failure of parturition in mice lacking the prostaglandin F receptor. *Science* 277: 681-684.
4. Takayama K *et al.* (2005) Thromboxane A2 and prostaglandin F_{2a} mediate inflammatory tachycardia. *Nat. Med.* 11: 562-566.

FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

No part of these works may be reproduced in any form without permission in writing.

User Agreement (Label License)

In addition to the General Terms and Conditions section, these specific terms also apply for **ChemiScreen™ FP Prostanoid Receptor Stable Cell Line, Product No. HTS093C**

BY USING THIS PRODUCT LICENSED TO YOU ("LICENSEE") HEREUNDER, YOU ARE HEREBY REPRESENTING THAT YOU HAVE THE RIGHT AND AUTHORITY TO LEGALLY BIND YOURSELF OR YOUR COMPANY, AS APPLICABLE, AND ARE CONSENTING TO BE LEGALLY BOUND BY ALL OF THE TERMS OF THIS USER AGREEMENT ("AGREEMENT"). IF YOU DO NOT AGREE TO ALL THESE TERMS, DO NOT USE THE PRODUCT, AND IMMEDIATELY RETURN SUCH PRODUCTS TO THE APPLICABLE SELLER FOR A REFUND. This is a legal agreement between Licensee and Eurofins Pharma Bioanalytics Services US Inc. governing use of the ChemiScreen™ Calcium-Optimized Stable GPCR cell line products and/or any accompanying operating/use protocols (the "Product(s)") provided to Licensee.

LICENSEE shall obtain no ownership interest in the Product or use/culture protocols accompanying the Product other than through the perpetual limited license granted herein. If the Product is licensed through an authorized Eurofins Pharma Bioanalytics Services US Inc. distributor, Licensee shall be obligated to disclose its identity to Eurofins Pharma Bioanalytics Services US Inc. to insure compliance with this User Agreement.

Limited License and Restrictions. Pursuant to the terms and conditions of this Agreement, Eurofins Pharma Bioanalytics Services US Inc. conveys to Licensee the non-exclusive and non-transferable right to use the Licensed Product only for Research Purposes conducted by Licensee (whether Licensee is an academic user or a for-profit entity). "Research Purposes" means any biological research and development application or use, including without limitation, developing, demonstrating or validating biological assays, life sciences and/or pharmaceutical research. "Research Purposes" excludes applications outside biology (including but not limited to consumer electronics or materials sciences), and specifically excludes the following applications of whatever kind or nature: Clinical Diagnostics (any use of a product or service for clinical diagnosis where data from an individual's sample is given to such individual or used for the purpose of diagnosis or treatment of a medical condition in such individual, where that result may be used in the treatment of such individual), therapeutics, clinical imaging, environmental testing and

cosmetics. Licensee cannot sell or otherwise transfer (a) this Product or (b) materials made using this Product to a third party. Licensee may transfer information or materials made through use of this Product to a scientific collaborator, provided that such transfer is not for the commercial purposes, and that such collaborator agrees in writing: (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for Research Purposes and not for commercial purposes. Commercial purposes means any activity by a user of the Product for consideration that may include, but is not limited to: (1) operating a service business that uses the Products to develop information or data which is resold for research and development applications; (2) use of the Product in manufacturing; (3) use of the Product for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the Product, whether or not such Product is resold for use in research. Licensee expressly represents and warrants to Eurofins Pharma Bioanalytics Services US Inc. that Licensee will properly test and use any Product purchased from Eurofins Pharma Bioanalytics Services US Inc. or its affiliated companies in accordance with the practices of a reasonable person who is an expert in the field and in strict compliance with all applicable laws and regulations, now and hereinafter enacted. Licensee agrees to comply with instructions, if any, furnished by Eurofins Pharma Bioanalytics Services US Inc. relating to the use of the Product and to not misuse the Product in any manner. Licensee shall not reverse engineer, disassemble or modify the Product or create any derivative works of the written materials accompanying the Product, including but not limited to any material data sheets or similar materials with respect to the Products' specifications. Licensee acknowledges that Eurofins Pharma Bioanalytics Services US Inc. or its affiliated companies retains ownership of all patents, copyrights, trademarks, trade secrets and other proprietary rights relating to or residing in the Product or any portion thereof.

Term and Termination. This Agreement commences upon Licensee's use of the Products, and shall remain in effect in perpetuity unless terminated sooner as set forth hereunder. Eurofins Pharma Bioanalytics Services US Inc. may terminate this Agreement immediately if Licensee breaches any provision herein. Upon any such termination, all rights granted to Licensee hereunder will immediately terminate, and Licensee shall immediately cease using the Product and, at Eurofins Pharma Bioanalytics Services US Inc.'s option, return or destroy all Products (certifying such destruction to Eurofins Pharma Bioanalytics Services US Inc. in writing).

Assignment. Licensee shall not sublicense, assign (by operation of law or otherwise) or otherwise transfer this Agreement or any of the rights or licenses granted under this Agreement without the prior written consent of Eurofins Pharma Bioanalytics Services US Inc.. Any attempted assignment, sublicense or transfer by Licensee without such consent shall be null and void.

Eurofins Pharma Bioanalytics Services US Inc. is an independent member of Eurofins Discovery Services